← Leaderboards
Mani Subramanian
Mitopower Llc
$3,242,612
Attributed
$6,485,223
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,485,223 · 1
By mechanism
U44$6,485,223 · 1
Top collaborators
- Shyamasundaran Kottilil5 shared
Others in their field
Other Emerging Leaders on “Hospitalization”
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Ted Ross · University Of Georgia$68,763,143
- Abraham Aizer Brody · New York University School Of Medicine$40,089,349
- Xinhua Li · Nano Terra, Inc.$32,991,103
- James Dale Berry · Brigham And Women'S Hospital$20,824,388
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$19,225,531
Research focus
HospitalizationHepatorenal SyndromeHistologyHepatocyteAcute ToxicityAlcoholsAnimal ModelHemodialysisBiogenesisHepaticCell PhysiologyAlcoholic Liver DiseasesDihydronicotinamideDna DamageDoseFirst-In-HumanFormulationFunctional DisorderFundingGene ExpressionGenotoxicityCanis FamiliarisHealthy VolunteerHuman Study
Grant awards (5)
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,499,999
U44 · FY2025 · AA · contact PI
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,500,000
U44 · FY2024 · AA · contact PI
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,500,000
U44 · FY2023 · AA · contact PI
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,000,000
U44 · FY2022 · AA · contact PI
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$985,224
U44 · FY2021 · AA · contact PI